Menu Search
Equities

Bristol-Myers Squibb Co

BRM:STU

Bristol-Myers Squibb Co

Actions
  • Price (EUR)52.57
  • Today's Change0.55 / 1.06%
  • Shares traded2.54k
  • 1 Year change3.57%
  • Beta--
Data delayed at least 15 minutes, as of Nov 23 2020.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.

  • Revenue in USD (TTM)39.40bn
  • Net income in USD-44.00m
  • Incorporated1933
  • Employees30.00k
  • Location
    Bristol-Myers Squibb Co430 E 29th St Fl 14NEW YORK 10016-8367United StatesUSA
  • Phone+1 (212) 546-4000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.bms.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		BMY:NYQ since
announced		Transaction
value
MyoKardia IncDeal completed05 Oct 202005 Oct 2020Deal completed6.83%13.77bn
Formation Biologics CorpDeal completed24 Aug 202024 Aug 2020Deal completed0.87%--
Data delayed at least 15 minutes, as of Nov 24 2020 15:37 GMT.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.